Global Veterinary Neurodegenerative Disease Diagnostics Market Assessment, By Product Type [Consumables, Reagents, and Kits, Equipment and Instruments], By Diagnostic Tests [Imaging, Biomarker Diagnostic Tests, Others], By Animal Type [Livestock, Companion], By Indication [Cognitive Dysfunction, Cerebellar Abiotrophy, Spongiform Encephalopathies, Others], By End-Use [Veterinary Hospitals and Clinics, Veterinary Diagnostic Laboratories, Others], By Region, Opportunities and Forecast, 2018-2032F

Global veterinary neurodegenerative disease diagnostics market is projected to witness a CAGR of 7.47% during the forecast period 2025-2032, growing from USD 0.40 billion in 2024 to USD 0.71 billion in 2032. The veterinary neurodegenerative disease diagnostics market continues to grow in a consistent manner, partially due to the increase in awareness of neurological disorders in animals and the need for early and accurate diagnostics. Many innovations in diagnostics have great significance and relevance to veterinary medicine, such as artificial intelligence-assisted imaging, portable imaging in the form of MRI, and molecular biomarker assessments. This is significantly changing the ways in which veterinarians detect, monitor and assess complex diseases in companion animals including cognitive dysfunction. Increased levels of pet ownership and the emotional bond that people have with their companion animals also influence the increased spending for specialty care.

Report Attribute	Details
Base Year	2024
Forecast Period	2025-2032F
Historical Period	2018-2023
Projected Growth Rate	CAGR of 7.47% between 2024 and 2032
Revenue Forecast in 2032	USD 0.71 billion

Additionally, the expansion of pet insurance and government-supported livestock insurance schemes is reducing cost-related barriers and enabling wider access to advanced diagnostics. Continuous technological innovation, combined with growing investment in veterinary research and improved clinical infrastructure, plays a vital role in shaping the future of this evolving market.

For instance, in October 2024, WOORIEN Co., Ltd. launched the MyVet CT Plus, a spiral-linear veterinary CT scanner featuring significantly faster scan and reconstruction times—reducing acquisition by up to 80%—and a flexible field-of-view suitable for animals from small reptiles to large dogs, making advanced imaging more accessible to diverse veterinary practices

Advancements in Diagnostic Technologies Driving Precision in Veterinary Neurodegenerative Disease Diagnostics

Veterinary neurodegenerative diagnostics is rapidly evolving with the integration of advanced technologies. Newer technologies, such as AI based imaging, high field MRI, and biomarker-based testing, will lead to earlier and more precise identification of complex neurological problems. In addition to offering more precise identification of disease, these technologies also provide improved characterization of the disease, assist with planning treatment, and provide ongoing assessment of treatment efficacy. The transition to digital systems and point-of-care diagnostics will enhance accessibility to diagnostics in all aspects of veterinary practice ranging from no/vet to urban/rural contexts. Advanced imaging, specifically MRI has evolved significantly in its ability to assess and identify subtle brain and spinal abnormalities. The ability progressively to document and assess a patient's disease over time will provide the veterinary clinician with substantial insights into disease progression and prognosis. Advances in technology are changing the landscape of veterinary neurology.

For instance, in June 2025, Siemens Healthineers gained FDA clearance for the Magnetom Flow.Ace 1.5 T MRI scanner, developed for both human and veterinary applications. Featuring AI-powered image reconstruction and an energy-efficient CoolDry helium system, the scanner enhances soft-tissue visualization, shortens scan durations, and adapts to diverse animal anatomies, marking a significant advancement in veterinary neurodiagnostic imaging.

Growing Pet Insurance Coverage Fuels Market Expansion

The increasing availability and uptake of pet insurance is one of the most important factors contributing to the growth of the veterinary neurodegenerative disease diagnostics market. Because diagnostic tools like MRIs, CTs, and biomarker tests can be expensive, insurance coverage opens up options for clients without the affordability barrier. Many policies now cover advanced diagnostic services; thus, veterinarians can now recommend full neurological evaluations without excess financial concern. This not only helps pet owners get an early and accurate diagnostic outcome when assessing if neurodegenerative disease is present, insurance had also opened the gate for veterinarians to adopt advanced technology by providing the immediate financial support necessary. The financial resources from insurance have quickened the pace of precision diagnostics and is helping to shape the future of the market.

For instance, in March 2025, according to Press Information Bureau, Government of India Under the National Livestock Mission (NLM), 21.01 lakh livestock animals were insured in the current financial year, supporting access to veterinary diagnostics, including neurodegenerative disease detection, by reducing financial barriers for farmers through demand-driven insurance coverage.

MRI Imaging Leads in Veterinary Neurodegenerative Diagnostics Market

MRI has emerged as the leading diagnostic tool in the veterinary neurodegenerative diagnostics market. As a non-invasive imaging technique, MRI excels at producing high-quality images of the brain and spinal cord, allowing for the identification of various conditions, regardless of their etiology, including cognitive dysfunction, cerebellar abiotrophy and other neurodegenerative diseases. MRI is set apart from other imaging techniques by its exceptional soft tissue contrast and absence of radiation exposure, making it a safer proposition. As a result, veterinary clinics and specialty hospitals are installing MRI systems into their practices to allow for rapid and accurate assessment of animals. The increase in demand for advanced neurological diagnostic testing provided to companion animals (dogs and cats) has further justified the use of MRI in a veterinary setting. With improved technology and availability of high-field MRI systems, this segment continues to gain momentum within the veterinary imaging market.

For instance, in October 2024, InkSpace Imaging LLC introduced the Nuzzle veterinary array, a new and innovative MRI coil that is approved for animal use. This will allow for much clearer, high-resolution images to drive detection and diagnosis of neurological diseases and disorders in the field of veterinary medicine.

North America Leads the Veterinary Neurodegenerative Diagnostics Market

North America holds a dominant position in the veterinary neurodegenerative diagnostics market. The main reason behind this is its well-developed veterinary healthcare system and high awareness among pet owners regarding neurological conditions in animals. The North America region is generally characterized by strong research and development funding, robust regulatory frameworks, strong veterinary healthcare systems, partnerships between academia, diagnostic developers, and commercialization support. The North America region has a large population of companion and performance animals along with an abundance of skilled veterinary professionals. The overall focus of North America is on the early and accurate detection of disease, and it has so far supported and sustained all the necessary elements to lead the way in veterinary neurodegenerative diagnostics.

For instance, in March 2025, NVIDIA Corporation and GE HealthCare Technologies Inc. announced a partnership to develop autonomous diagnostic imaging systems using physical AI. This collaboration leverages simulation and robotics to improve imaging accuracy and efficiency in clinical settings.

Download Free Sample Report

Impact of U.S. Tariffs on Veterinary Neurodegenerative Disease Diagnostics Market   

• Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.
• Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries. Companies may select to work with domestic suppliers or alternate suppliers, which affect time.
• Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.
• Higher prices and lower availability may inhibit any growth of the market in the interim time.

Report Scope

“Global Veterinary Neurodegenerative Disease Diagnostics Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global veterinary neurodegenerative disease diagnostics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecasts between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Product Type, Diagnostic Tests, Animal Type, Indication, End-Use
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profiled	Zoetis Inc., Virbac SA, Life Diagnostics, Inc., ACUVET Biotech, Merck Animal Health (Merck & Co., Inc.), IDEXX Laboratories, Inc., MI:RNA Diagnostics Ltd., Mercodia AB, Antech Diagnostics, Inc., Avacta Animal Health Limited
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global veterinary neurodegenerative disease diagnostics market has been segmented into the following categories: 

• By Product Type
  • Consumables, Reagents, and Kits
  • Equipment and Instruments
• By Diagnostic Tests
  • Imaging
    • MRI (Magnetic Resonance Imaging)
    • CT (Computed Tomography)
    • Others
  • Biomarker Diagnostic Tests
    • CSF (Cerebrospinal Fluid) Biomarkers
    • Blood-based Biomarkers
    • Others
  • Others
• By Animal Type
  • Livestock
    • Sheep
    • Cattle
    • Others
  • Companion
    • Canine
    • Feline
    • Equine
    • Others
  • By Indication
    • Cognitive Dysfunction
    • Cerebellar Abiotrophy
    • Spongiform Encephalopathies
    • Others
  • By End-Use
    • Veterinary Hospitals and Clinics
    • Veterinary Diagnostic Laboratories
    • Others
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East and Africa

Key Players Landscape and Outlook

The key players operating the market are focusing on innovation, strategic partnerships, and continuing advancements in diagnostics. Their priority is to the develop improved tools for the early detection of neurodegenerative diseases in the veterinary setting. Most of the companies are investing in artificial intelligence and digital image assessment tools to improve accuracy and efficiency of diagnostics. Others are emphasizing point-of-care testing to provide rapid diagnostics in a clinical environment. Many are emphasizing the expansion of laboratory networks as well as the integration of diagnostics with the treatment protocols. Other companies are partnering with research institutions to assess new biomarkers and neuroimaging. The greater usage of cloud-based diagnostic resources is expediting diagnostic workflows and promoting processes that allow data transfer sharing. Thus, the focus is on technological advancement, accessibility, and achieving better diagnostic decisions about difficult neurodegenerative issues in animals.

For instance, in January 2025, Zoetis Inc. launched an enhanced Vetscan Imagyst with 6-in-1 AI-powered diagnostics, including blood, fecal, dermatology, and urine analysis, advancing speed and accuracy in veterinary neuro diagnostics.

Key Players Operating in Global Veterinary Neurodegenerative Disease Diagnostics Market are:

• Zoetis Inc.
• Virbac SA
• Life Diagnostics, Inc.
• ACUVET Biotech
• Merck Animal Health (Merck & Co., Inc.)
• IDEXX Laboratories, Inc.
• MI:RNA Diagnostics Ltd.
• Mercodia AB
• Antech Diagnostics, Inc.
• Avacta Animal Health Limited

If you can't find what you're searching for or have any custom requirements for global veterinary neurodegenerative disease diagnostics market, you may approach our team at info@marketsandata.com.